Atossa Genetics (ATOS) Expected to Post Quarterly Earnings on Wednesday

Atossa Genetics (NASDAQ:ATOS) is expected to be issuing its Q3 2026 resultson Wednesday, November 11th. Analysts expect Atossa Genetics to post earnings of ($0.86) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.07. On average, analysts expect Atossa Genetics to post ($3.75) EPS for the current fiscal year and ($2.78) EPS for the next fiscal year.

Atossa Genetics Stock Performance

NASDAQ:ATOS opened at $2.33 on Wednesday. The firm has a 50-day moving average price of $2.41 and a two-hundred day moving average price of $3.91. Atossa Genetics has a twelve month low of $1.70 and a twelve month high of $14.85.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Wall Street Zen raised shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Atossa Genetics in a research note on Tuesday, September 8th. Finally, Rodman & Renshaw initiated coverage on Atossa Genetics in a report on Tuesday, July 7th. They set a “buy” rating and a $12.00 target price on the stock. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.33.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast-related conditions. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s lead program is (Z)-endoxifen, an oral selective estrogen receptor modulator being investigated primarily for estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.